Loading...
XKRX010600
Market cap33mUSD
Apr 05, Last price  
545.00KRW
Name

WellBiotec Co Ltd

Chart & Performance

D1W1MN
XKRX:010600 chart
P/E
—
P/S
0.69
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
31.74%
Rev. gr., 5y
-0.49%
Revenues
72.13b
-62.22%
112,671,917,00098,179,133,00073,916,511,00086,836,584,000119,782,624,540136,748,152,860137,762,428,120119,630,043,690112,488,077,21085,292,458,50070,785,770,56073,932,352,31083,816,105,78060,431,404,730121,623,324,840190,937,399,35072,132,464,140
Net income
-64.91b
L+911.29%
-6,424,073,000-27,664,399,000-10,708,758,000-12,846,928,0001,581,589,420-2,946,007,0002,373,558,000-6,655,133,400550,244,150-2,450,152,000-8,742,014,280-15,565,917,620-16,552,641,460-50,907,598,070-21,213,649,860-6,418,574,850-64,910,322,280
CFO
-4.17b
L
-891,690,0003,109,325,000-2,044,471,0002,903,495,000-246,005,3503,058,896,6901,010,203,010-1,534,357,9704,277,476,170-2,365,591,060-4,018,127,150-9,274,913,070-7,727,487,400-5,704,812,820712,970,1202,623,413,840-4,168,140,350
Dividend
Dec 28, 2005123.57275 KRW/sh

Profile

Wellbiotec Co., Ltd. produces and sells leather products in South Korea and internationally. The company provides leather products for shoes, bags, car seats, and handle covers. It also offers logistics consulting, container, warehouse/clearance, and transportation agency services; product research and development, consulting, distribution, and sales; and general and specialized medicines, health functional products, diagnosis kits, cosmeceuticals, and other products. In addition, the company is involved in casting agency, celebrity development, content production, and multi-channel network; and food and beverages businesses. The company was founded in 1975 and is headquartered in Seoul, South Korea.
URL
http://www.wellbiotec.co.kr/
IPO date
Jul 18, 1997
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
72,132,464
-62.22%
190,937,399
56.99%
Cost of revenue
70,123,780
175,138,315
Unusual Expense (Income)
NOPBT
2,008,684
15,799,085
NOPBT Margin
2.78%
8.27%
Operating Taxes
516,469
1,391,356
Tax Rate
25.71%
8.81%
NOPAT
1,492,215
14,407,728
Net income
(64,910,322)
911.29%
(6,418,575)
-69.74%
Dividends
Dividend yield
Proceeds from repurchase of equity
8,000,000
(30,061)
BB yield
-8.38%
0.04%
Debt
Debt current
6,566,159
4,020,916
Long-term debt
4,364,316
603,058
Deferred revenue
Other long-term liabilities
754,447
1,222,888
Net debt
(26,462,824)
(11,763,179)
Cash flow
Cash from operating activities
(4,168,140)
2,623,414
CAPEX
(1,082,713)
(508,762)
Cash from investing activities
(22,630,406)
15,887,624
Cash from financing activities
26,479,873
(11,788,332)
FCF
11,908,370
35,600,884
Balance
Cash
21,383,580
14,675,952
Long term investments
16,009,720
1,711,201
Excess cash
33,786,676
6,840,284
Stockholders' equity
(68,342,540)
28,839,323
Invested Capital
114,579,495
34,895,975
ROIC
2.00%
18.59%
ROCE
4.34%
37.85%
EV
Common stock shares outstanding
79,197
64,324
Price
1,205.00
13.15%
1,065.00
-39.66%
Market cap
95,432,598
39.31%
68,504,713
-29.88%
EV
116,884,541
57,275,777
EBITDA
3,481,837
17,159,943
EV/EBITDA
33.57
3.34
Interest
791,125
Interest/NOPBT
5.01%